ArticleThe patient2026
Communicating Change on Multi-item Patient-Reported Outcome Measures: What Were the Meaningful Changes in Physical Functioning Experienced by Patients on Vimseltinib in the MOTION Trial.
Article in The patient, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05059262 (A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor (MOTION)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivePatients with tenosynovial giant cell tumor experience many impacts on their physical functioning associated with pain, stiffness, and limited range of motion. Clinical trials often use clinical outcome assessments to establish meaningful change in treatment; although, conceptualizing improvement on a multi-item measure can be challenging. The goal of this analysis was to explicitly characterize what the significant and meaningful improvements in physical functioning were among those who were considered physical functioning responders.
methodsA mixed-method analysis was conducted using data from the MOTION phase III trial (NCT05059262) and in-trial exit interviews conducted prior to unblinding. A heat map was developed to characterize individual patient- and item-level data improvements in physical functioning among those on vimseltinib considered responders (change of ≥ 3 points on total score) on the Patient-Reported Outcomes Measurement Information System-Physical Functioning short form (PROMIS-PF
resultsA total of 36 participants (n = 36/83, 43%) in the vimseltinib treatment group were PROMIS-PF responders. Patients in this group had more than a one-category improvement in 12 of the 15 items and 64-100% of the participants improved on each PROMIS-PF item. Exit interview participants described meaningful improvements in physical functioning from the patient perspective, including better mobility, greater independence, and the ability to resume work, daily activities, and recreational activities.
conclusionsPatients with tenosynovial giant cell tumor showed meaningful improvement in physical functioning on vimseltinib. Item- and individual patient-level characterization of these improvements can be utilized in communication for treatment decision making between clinicians and patients. This method may be utilized in other measures and indications to generate information when considering treatment options.
Identifiers
42758392What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.